# ATTACHbio

Source: https://onco.cc/companies/attachbio/  
OnCo record `attachbio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ATTACHbio has a laboratory method that picks out the immune T cells in a patient's tumour that recognise the cancer, without first knowing what they recognise, to help build personalised cell treatments.

## Summary

ATTACHbio develops the ATTACH platform (Assessment of T cells Tethered to Antigen Class I Histocompatibility), which isolates antigen-specific CD8 T cells from patient tumour samples without prior knowledge of the antigen or HLA type. The platform came from Alexandre Reuben's laboratory at MD Anderson Cancer Center, where it was developed for lung cancer cell therapy. In fiscal year 2026 NCI awarded it USD 349,889 under STTR award 1R41CA314843-01 for the platform in non-small cell lung cancer.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: AttachBio LLC; ATTACHBIO LLC
- HQ: Missouri City, TX
- Type: biotech
- Website: https://attachbio.com/

## Notes

- A discovery platform, not a medicine. Read on attachbio.com and NIH RePORTER on 4 November 2026.

## Sources

- Official website: https://attachbio.com/
- NIH RePORTER: STTR award 1R41CA314843-01: https://reporter.nih.gov/project-details/11410217

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [TIL therapy](https://onco.cc/technologies/til-therapy/)

---
JSON: https://onco.cc/api/v1/entities/attachbio.json